Compare Ascendis Pharma A/S (ASND) vs Avient Corporation (AVNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Avient Corporation — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Avient Corporation trades at $35.51 (market cap $3.30B). The key difference: Ascendis Pharma A/S is far larger — about 5.4× Avient Corporation's market cap, and Avient Corporation pays a 3.05% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | AVNT | |
|---|---|---|
Market Cap | $17.74B | $3.30B |
Sector | Health | Technology |
52-Week High | $277.18 | $43.28 |
52-Week Low | $163.32 | $27.48 |
Enterprise Value | $18.11B | $4.80B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Avient Corporation (AVNT) trades at $36.03, showing modest daily gains of 0.14%. The stock exhibits bearish technical signals with moving averages and ADX indicators pointing downward, though RSI levels remain neutral. Fundamentally, the company maintains stable revenue around $3.3 billion with improving profitability, as evidenced by three consecutive quarterly earnings beats. Recent product launches in barrier technology and dielectric thermoplastics demonstrate innovation in materials solutions.
Avient presents a mixed investment case with strong analyst support (60% buy ratings) offset by technical weakness. The company's consistent earnings performance and dividend payments provide stability, while competitive pressures and market volatility remain key risks. Near-term catalyst includes Q2 2026 earnings release on August 6, 2026, where the company faces expectations of $0.89 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →
